Overview

A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine

Status:
NOT_YET_RECRUITING

Trial end date:
2026-02-06

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).

Phase:

PHASE2

Details

Lead Sponsor:

Clear Scientific, Inc.

Collaborator:

National Institute on Drug Abuse (NIDA)

Treatments:

Methamphetamine